Comparative Pharmacology
Head-to-head clinical analysis: AEROLATE SR versus BRONKOSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLATE SR versus BRONKOSOL.
AEROLATE SR vs BRONKOSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (cAMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Bronchodilator via beta-2 adrenergic receptor agonism, increasing intracellular cAMP, leading to smooth muscle relaxation in the airways.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
2.5 mg (0.5 mL of 0.5% solution) via nebulization three to four times daily, as needed.
None Documented
None Documented
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Terminal elimination half-life is 3–4 hours; prolonged in hepatic impairment (up to 8 hours).
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Primarily renal excretion as sulfate conjugates; unchanged drug accounts for <10% of excretion. Biliary/fecal excretion is minimal (<2%).
Category C
Category C
Bronchodilator
Bronchodilator